SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| CONSTELLATION TECHNOLOGIES LIMITED | 04/06/2020 | |
| CCP TECHNOLOGIES LIMITED | 23/11/2016 | 04/06/2020 |
| AGENIX LIMITED | 22/06/2001 | 23/11/2016 |
| BIOTECH INTERNATIONAL LIMITED | 06/07/1989 | 22/06/2001 |
| UNIFUND AUSTRALIA LIMITED | 06/07/1989 |
110 Stirling Hwy, Nedlands WA 6009
Tel : +61 8 9389 8033name changed to Constellation Technologies Limited | 04/06/2020 |
The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately following the release by CT1 of an announcement regarding its non-renounceable entitlement issue. | 18/10/2019 |
The company announces a one for one non-renounceable pro rata entitlement issue. One free attaching option for each share applied for will be granted. The rights issue will be availalbe to holders of shaers in the company with a registered address in Australia and New Zealand as at 24 October 2019. | 18/10/2019 |
The securities of CCP Technologies Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CT1, pending the release of an announcement regarding the final execution of agreements relating to the entitlement offer. | 17/10/2019 |
The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately following the release by CT1 of an announcement advising that it has withdrawn from discussions in relation to a potential acquisition. | 24/07/2019 |
The company has withdrawn from the potential corporate transaction discussions. There were and are no binding commercial terms in place in respect to the potential transaction. The company will focus on other commercial and potential corporate opportunities. | 24/07/2019 |
The company has received commitments from investors to raise $576,592 by issue of 44,353,252 new ordinary shares at $0.013 per share. The shares will be issued from the company's remaining placement capacity under Listing Rule 7.1. The company seeks an extension of the suspension of its securities in order to further progress the discussions in connection with the potential corporate transaction and to subsequently finalise an announcement in relation to those discussions. The company expects to make an announcement regarding this by the commencement of trade on 24 July 2019. | 19/07/2019 |
The securities of CCP Technologies Limited will be suspended from quotation immediately under ListingbRule 17.2, at the request of CT1, pending the release of an announcement regarding proposed capital raising and the potential corporate transaction. | 17/07/2019 |
The suspension of trading in the securities of CCP Technologies Limited will be lifted immediately, following release of an announcement of a proposed capital raising and the Company's response to an ASX Query. | 17/07/2018 |
The company issues a response to an ASX query. | 17/07/2018 |
The company has received commitments from strategic investors to raise $861,247 (before costs) by issue of 43,062,350 new ordinary shares at $0.02 per share. Each subscriber in the placement will also receive a two-year unlisted option, for each share issued, with an exercise price of $0.03, subject to shareholder approval at the Company's 2018 Annual General Meeting. CCP welcomes Penta Global Blockchain Foundation and First Growth Funds to the register. The company also announces the acceleration of CCP's blockchain initiatives. | 17/07/2018 |
The securities of CCP Technologies Limited will be suspended from quotation immediately, in accordance with Listing Rule 17.3, pending the release of a satisfactory announcement in relation to the Company's proposed capital raising. | 13/07/2018 |
name changed from Agenix Limited | 23/11/2016 |
The global cardiovascular monitoring and diagnostic devices market to reach nearly US$ 8 Billion by 2021, growing at a CAGR of 9.0% from 2017 to 2021. Market by device or product type (ECG systems, resting ECG systems, stress ECG systems, cardiovascular diagnostic catheters, event monitors, Holter monitors, implantable loop recorders, ECG management systems). Major players are Boston Scientific Corporation, Covidien plc, FUKUDA DENSHI Co., Ltd., GE Healthcare, Johnson & Johnson, Medtronic, Inc, Nihon Kohden Corporation, Philips Healthcare, Siemens Healthcare, Sorin Group, Spacelabs Healthcare, St. Jude Medical, Inc and Welch Allyn, Inc. https://www.ihealthcareanalyst.com/report/cardiovascular-monitoring-diagnostic-devices-market/ | 27/12/2017 00:17:24 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 18/10/2019 | Anoosh Manzoori | 1,000,000 | $0.012 | $12,000.00 |
| 19/09/2017 | Adam Gallagher | 395,000 | $0.019 | $7,632.00 |
| 07/09/2017 | Anthony Rowley | 85,000 | $0.024 | $2,037.00 |
| 27/04/2017 | Michael White | 50,000 | $0.022 | $1,122.00 |
| 21/04/2017 | Anthony Rowley | 868,500 | $0.018 | $16,002.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Leath Nicholson | Non Exec Chairman, Independent Director | 14/10/2016 |
| Terri Bakos | CFO, Company Secretary | 01/01/2019 |
| Anoosh Manzoori | Independent Director | 14/10/2016 |
| Adam Gallagher | Director, CEO | 01/06/2015 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
